C3 and chronic kidney disease: The non-PEGylated C3 inhibitor compstatin analogue AMY-101 has been developed by Amyndas Pharmaceuticals and they have already announced plans to develop this C3-targeted inhibitor as a treatment option for prevention of organ rejection during kidney transplantation and treatment of patients with end-stage renal disease (ESRD) [85].